What to know about Merck's acquisition of Acceleron Pharma скачать в хорошем качестве

What to know about Merck's acquisition of Acceleron Pharma

CNBC's David Faber breaks down why Merck's $11.5 billion acquisition of Acceleron Pharma could be a risky play. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi Merck is buying Acceleron Pharma for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh revenue. The deal gives Merck access to Acceleron’s rare disease drug candidate, sotatercept, which the company expects to be a multi-billion dollar peak sales opportunity, and comes as Keytruda moves toward the loss of market exclusivity in 2028. The lung cancer treatment accounted for 36.7%, or $4.18 billion, of Merck’s total sales in the second quarter. Sotatercept is currently in a late-stage study, testing it as a treatment for a rare cardiovascular disease called pulmonary arterial hypertension (PAH), a type of high blood pressure that affects blood vessels in the lungs. Merck sees PAH as a roughly $7.5 billion market by 2026. The drugmaker will pay $180 per Acceleron share in cash, representing a premium of about 2.6% to the stock’s closing price on Wednesday, according to Refinitiv data. Although the Acceleron deal will not fully remove the overhang of generic competition for Keytruda, it does help diversify sales, which addresses a large shareholder concern, Cantor Fitzgerald analyst Louise Chen wrote in a client note. Merck is targeting a U.S. launch for sotatercept in 2024-2025 and its market exclusivity for PAH is expected to extend through 2036-2037. The deal also adds the FDA-approved blood-related disorder drug, Reblozyl - which Acceleron markets with partner Bristol Myers Squibb - to Merck’s portfolio. The transaction is expected to close in the fourth quarter. » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-n... Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Facebook: Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC https://www.cnbc.com/select/best-cred... #CNBC #CNBCTV